Literature DB >> 22750540

Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein.

Ianko D Iankov1, Alan R Penheiter, Stephanie K Carlson, Evanthia Galanis.   

Abstract

Neutrophil-activating protein (NAP) is a major virulence factor expressed by Helicobacter pylori isolates associated with severe chronic gastroduodenal inflammation and peptic ulcers. NAP is one of the main protective antigens and a target for vaccine development against Helicobacter infection. In addition, NAP is a potent immune stimulator with potential application as a general vaccine adjuvant and in treatment of allergic diseases and cancer immunotherapy. NAP-specific immunoassays are needed for both H. pylori diagnostics and characterization of NAP-based vaccines and immunomodulatory preparations. We generated a panel of NAP-specific monoclonal antibodies (MAbs) by immunization of BALB/c mice with synthetic NAP peptides. The antibody reactivity against recombinant or native NAP antigen was characterized by enzyme-linked immunosorbent assay (ELISA), immunoblotting and immunofluorescence. A sensitive capture ELISA was developed using MAbs 23C8 and 16F4 (directed against different NAP epitopes) for detection of native or measles virus (MV) vector-expressed recombinant NAP in a concentration range of 4 ng/ml to 2000 ng/ml. MAb 23C8 antigen-binding depends on Tyr101 in a variable amino acid sequence of the NAP molecule, indicating the existence of antigenic variants among H. pylori strains. MAb 16F4 reacted with NAP from different H. pylori strains and was a sensitive tool for detection of small amounts of isolated NAP antigen or whole bacteria by immunoblotting or immunofluorescence. In conclusion, MAb-based immunoassays are highly specific and sensitive for detection of native NAP antigen and recombinant NAP immunostimulatory transgenes expressed by replication competent virus vectors.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750540      PMCID: PMC3691681          DOI: 10.1016/j.jim.2012.06.010

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  35 in total

Review 1.  Diagnosis of Helicobacter pylori.

Authors:  Meltem Yalinay Cirak; Yakut Akyön; Francis Mégraud
Journal:  Helicobacter       Date:  2007-10       Impact factor: 5.753

Review 2.  The design of vaccines against Helicobacter pylori and their development.

Authors:  G Del Giudice; A Covacci; J L Telford; C Montecucco; R Rappuoli
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Comparison of a monoclonal antigen stool test (Hp StAR) with the 13C-urea breath test in monitoring Helicobacter pylori eradication therapy.

Authors:  Francesco Perri; Michele Quitadamo; Rosalba Ricciardi; Ada Piepoli; Rosa Cotugno; Annamaria Gentile; Alberto Pilotto; Angelo Andriulli
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

4.  Helicobacter pylori neutrophil-activating protein promotes myeloperoxidase release from human neutrophils.

Authors:  Chung-An Wang; Yen-Chun Liu; Shin-Yi Du; Chio-Wen Lin; Hua-Wen Fu
Journal:  Biochem Biophys Res Commun       Date:  2008-09-25       Impact factor: 3.575

Review 5.  Helicobacter pylori diagnostic tests in children: review of the literature from 1999 to 2009.

Authors:  Jeannette Guarner; Nicolas Kalach; Yoram Elitsur; Sibylle Koletzko
Journal:  Eur J Pediatr       Date:  2009-07-18       Impact factor: 3.183

6.  The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses.

Authors:  Amedeo Amedei; Andrea Cappon; Gaia Codolo; Anna Cabrelle; Alessandra Polenghi; Marisa Benagiano; Elisabetta Tasca; Annalisa Azzurri; Mario Milco D'Elios; Gianfranco Del Prete; Marina de Bernard
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

7.  Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.

Authors:  Peter Malfertheiner; Viola Schultze; Bernd Rosenkranz; Stefan H E Kaufmann; Timo Ulrichs; Deborah Novicki; Francesco Norelli; Mario Contorni; Samuele Peppoloni; Duccio Berti; Daniela Tornese; Jitendra Ganju; Emanuela Palla; Rino Rappuoli; Bruce F Scharschmidt; Giuseppe Del Giudice
Journal:  Gastroenterology       Date:  2008-05-28       Impact factor: 22.682

Review 8.  VacA and HP-NAP, Ying and Yang of Helicobacter pylori-associated gastric inflammation.

Authors:  Mario Milco D'Elios; Cesare Montecucco; Marina de Bernard
Journal:  Clin Chim Acta       Date:  2007-02-21       Impact factor: 3.786

9.  The effect of Helicobacter pylori on asthma and allergy.

Authors:  Amedeo Amedei; Gaia Codolo; Gianfranco Del Prete; Marina de Bernard; Mario M D'Elios
Journal:  J Asthma Allergy       Date:  2010-09-29

10.  The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor.

Authors:  B Satin; G Del Giudice; V Della Bianca; S Dusi; C Laudanna; F Tonello; D Kelleher; R Rappuoli; C Montecucco; F Rossi
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  7 in total

1.  A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.

Authors:  Cheyne Kurokawa; Ianko D Iankov; Evanthia Galanis
Journal:  Virus Res       Date:  2019-01-23       Impact factor: 3.303

Review 2.  Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications.

Authors:  Hua-Wen Fu
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

3.  Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

Authors:  Ianko D Iankov; Mark J Federspiel; Evanthia Galanis
Journal:  Vaccine       Date:  2013-08-12       Impact factor: 3.641

4.  Helicobacter pylori Neutrophil-Activating Protein Directly Interacts with and Activates Toll-like Receptor 2 to Induce the Secretion of Interleukin-8 from Neutrophils and ATRA-Induced Differentiated HL-60 Cells.

Authors:  Shao-Hsuan Wen; Zhi-Wei Hong; Chung-Chu Chen; Han-Wen Chang; Hua-Wen Fu
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

5.  Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H . pylori immunostimulatory bacterial transgene.

Authors:  Kimberly B Viker; Michael B Steele; Ianko D Iankov; Susanna C Concilio; Arun Ammayappan; Brad Bolon; Nathan J Jenks; Matthew P Goetz; Eleni Panagioti; Mark J Federspiel; Minetta C Liu; Kah Whye Peng; Evanthia Galanis
Journal:  Mol Ther Methods Clin Dev       Date:  2022-07-31       Impact factor: 5.849

6.  Monoclonal antibody targeting complement C9 binding domain of Trichinella spiralis paramyosin impairs the viability of Trichinella infective larvae in the presence of complement.

Authors:  Yuwan Hao; Xi Zhao; Jing Yang; Yuan Gu; Ran Sun; Xinping Zhu
Journal:  Parasit Vectors       Date:  2014-07-04       Impact factor: 3.876

7.  Detection and genotyping of Helicobacter pylori in saliva versus stool samples from asymptomatic individuals in Northeastern Thailand reveals intra-host tissue-specific H. pylori subtypes.

Authors:  Phattharaphon Wongphutorn; Chariya Chomvarin; Banchob Sripa; Wises Namwat; Kiatichai Faksri
Journal:  BMC Microbiol       Date:  2018-01-30       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.